Investigational Drug Information for KAE609
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug KAE609?
KAE609 is an investigational drug.
There have been 8 clinical trials for KAE609. The most recent clinical trial was a Phase 2 trial, which was initiated on September 14th 2023.
The most common disease conditions in clinical trials are Malaria, Malaria, Falciparum, and Malaria, Vivax. The leading clinical trial sponsors are Novartis Pharmaceuticals, Wellcome Trust, and European and Developing Countries Clinical Trials Partnership (EDCTP).
Summary for KAE609
|US Patent Applications||47|
|WIPO Patent Applications||37|
|Japanese Patent Applications||7|
|Clinical Trial Progress||Phase 2 (2023-09-14)|
Recent Clinical Trials for KAE609
|Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria||Novartis Pharmaceuticals||Phase 2|
|To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria||EDCTP within the PAMAFRICA Grant||Phase 2|
|To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria||European and Developing Countries Clinical Trials Partnership (EDCTP)||Phase 2|
Clinical Trial Summary for KAE609
Top disease conditions for KAE609
Top clinical trial sponsors for KAE609
US Patents for KAE609
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|